Aims & Scope
The Journal of Alzheimers Disease is a peer-reviewed, open-access journal from Directive Publications dedicated to the science, diagnosis, treatment, and care of Alzheimer's disease and related neurodegenerative disorders.
The journal welcomes work across the full translational spectrum: amyloid-beta and tau biomarkers, neuroimaging, mild cognitive impairment, Lewy body dementia, vascular and frontotemporal dementia, and Parkinson's disease and parkinsonism. We particularly encourage studies on neuroprotection, non-pharmacological and e-health interventions, assistive technologies, activities of daily living, and quality of life and well-being for patients and caregivers.
We publish original research, systematic and narrative reviews, clinical case reports, methodological papers, and editorials. Every submission undergoes double-blind peer review; accepted articles appear open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright.
The journal follows COPE ethical principles, and article-processing charges apply on acceptance with waivers and discounts available.
Subject Coverage
The Journal of Alzheimer's Disease welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in The Journal of Alzheimer's Disease — explore related research across our journals.
Articles
Frequently Asked Questions
What topics does The Journal of Alzheimers Disease cover?
The journal covers Alzheimer's disease and the broader spectrum of neurodegenerative and dementia research, including amyloid and tau biomarkers, mild cognitive impairment, Lewy body dementia, vascular and frontotemporal dementia, and Parkinson's disease and parkinsonism. It also welcomes studies on neuroprotection, non-pharmacological and e-health interventions, assistive technology, activities of daily living, and quality of life for patients and caregivers.
Who should read and publish in The Journal of Alzheimers Disease?
The journal is intended for neurologists, geriatricians, neuroscientists, neuropsychologists, gerontologists, dementia-care researchers, and clinical practitioners. Researchers studying any aspect of Alzheimer's disease, dementia, or neurodegeneration, from basic mechanisms to clinical care and quality of life, are encouraged to submit.
How do I submit a manuscript to The Journal of Alzheimers Disease?
Visit the journal's Submit page and follow the author guidelines for formatting and ethics requirements. Submissions are accepted year-round and enter double-blind peer review. The journal welcomes original research, reviews, clinical case reports, methodological papers, and editorials in Alzheimer's and neurodegenerative disease.
Is The Journal of Alzheimers Disease open access, and who holds copyright?
Yes. All accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, and authors retain copyright. This means readers worldwide can freely access, read, and cite Alzheimer's and dementia research published in the journal.
Are there article-processing charges or fee waivers?
An article-processing charge applies on acceptance to sustain open-access publication, editorial handling, and permanent archiving. Waivers and discounts are available; authors who need fee support, including those from lower-income settings, are encouraged to request a waiver during submission.
What article types does The Journal of Alzheimers Disease accept?
The journal accepts original research articles, systematic and narrative reviews, clinical and translational case reports, short communications, methodological papers, and editorials addressing Alzheimer's disease, dementia subtypes, Parkinson's disease, neuroprotection, and patient care and quality of life.